METRODORA
Dead / Abandoned — Abandoned — no statement of use filed (as of 01 Oct 2025)
What this means for you
This application is over — abandoned 01 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97023419
- Mark type
- Stylized text
- Filed
- 12 Sept 2021
- Published for opposition
- 28 Mar 2023
- Abandoned
- 01 Oct 2025
- Attorney of record
- Alexander J. Kim
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; pharmaceutical preparations for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; therapeutic pharmaceuticals for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; medical preparations for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; prescription diets, namely, dietetic foods and nutritional and dietary supplements provided by prescription for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries
Owner
- Metrodora Institute LLC, Salt Lake City, UT, US
- Metrodora Institute LLC, Salt Lake City, UT, US
Prosecution history
- 01 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 01 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 24 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 May 2024 — SOU EXTENSION 2 GRANTED
- 23 May 2024 — SOU EXTENSION 2 FILED
- 23 May 2024 — SOU TEAS EXTENSION RECEIVED
- 16 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Nov 2023 — SOU EXTENSION 1 GRANTED
- 14 Nov 2023 — SOU EXTENSION 1 FILED
- 14 Nov 2023 — SOU TEAS EXTENSION RECEIVED
- 23 May 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Mar 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Mar 2023 — PUBLISHED FOR OPPOSITION
- 08 Mar 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Feb 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER